188 related articles for article (PubMed ID: 34997154)
1. The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer.
Reich LA; Moerland JA; Leal AS; Zhang D; Carapellucci S; Lockwood B; Jurutka PW; Marshall PA; Wagner CE; Liby KT
Sci Rep; 2022 Jan; 12(1):293. PubMed ID: 34997154
[TBL] [Abstract][Full Text] [Related]
2. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Moerland JA; Zhang D; Reich LA; Carapellucci S; Lockwood B; Leal AS; Krieger-Burke T; Aleiwi B; Ellsworth E; Liby KT
Sci Rep; 2020 Dec; 10(1):22244. PubMed ID: 33335263
[TBL] [Abstract][Full Text] [Related]
3. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
Zhang D; Leal AS; Carapellucci S; Shahani PH; Bhogal JS; Ibrahim S; Raban S; Jurutka PW; Marshall PA; Sporn MB; Wagner CE; Liby KT
Cancer Prev Res (Phila); 2019 Apr; 12(4):211-224. PubMed ID: 30760500
[TBL] [Abstract][Full Text] [Related]
4. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.
Li Y; Zhang Y; Hill J; Kim HT; Shen Q; Bissonnette RP; Lamph WW; Brown PH
Br J Cancer; 2008 Apr; 98(8):1380-8. PubMed ID: 18362934
[TBL] [Abstract][Full Text] [Related]
5. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
[TBL] [Abstract][Full Text] [Related]
6. Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray.
Seo HS; Woo JK; Shin YC; Ko SG
Mol Med Rep; 2015 Jul; 12(1):800-18. PubMed ID: 25778982
[TBL] [Abstract][Full Text] [Related]
7. Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands.
Han JS; Crowe DL
BMC Cancer; 2010 Nov; 10():629. PubMed ID: 21080969
[TBL] [Abstract][Full Text] [Related]
8. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
9. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
Jurutka PW; Wagner CE
Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
[TBL] [Abstract][Full Text] [Related]
10. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Brown PH; Subbaramaiah K; Salmon AP; Baker R; Newman RA; Yang P; Zhou XK; Bissonnette RP; Dannenberg AJ; Howe LR
Cancer Prev Res (Phila); 2008 Aug; 1(3):208-14. PubMed ID: 19138958
[TBL] [Abstract][Full Text] [Related]
11. Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models.
Leal AS; Zydeck K; Carapellucci S; Reich LA; Zhang D; Moerland JA; Sporn MB; Liby KT
NPJ Breast Cancer; 2019; 5():39. PubMed ID: 31700995
[TBL] [Abstract][Full Text] [Related]
12. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
13. A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics.
Hanish BJ; Hackney Price JF; Kaneko I; Ma N; van der Vaart A; Wagner CE; Jurutka PW; Marshall PA
Steroids; 2018 Jul; 135():36-49. PubMed ID: 29704526
[TBL] [Abstract][Full Text] [Related]
14. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
16. Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors.
Qi L; Guo Y; Zhang P; Cao X; Luan Y
Curr Drug Metab; 2016; 17(2):118-28. PubMed ID: 26806040
[TBL] [Abstract][Full Text] [Related]
17. The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice.
Reich LA; Leal AS; Ellsworth E; Liby KT
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901727
[TBL] [Abstract][Full Text] [Related]
18. Bexarotene induces cellular senescence in MMTV-Neu mouse model of mammary carcinogenesis.
Shilkaitis A; Bratescu L; Green A; Yamada T; Christov K
Cancer Prev Res (Phila); 2013 Apr; 6(4):299-308. PubMed ID: 23430755
[TBL] [Abstract][Full Text] [Related]
19. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
20. Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer.
Cras A; Politis B; Balitrand N; Darsin-Bettinger D; Boelle PY; Cassinat B; Toubert ME; Chomienne C
Clin Cancer Res; 2012 Jan; 18(2):442-53. PubMed ID: 22142826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
